UniDoc Closes Fully Subscribed LIFE Offering
Rhea-AI Summary
UniDoc Health (OTCQB:UDOCF) closed a fully subscribed non-brokered private placement LIFE offering on October 27, 2025, issuing 10,000,000 units at $0.15 per unit for aggregate gross proceeds of $1,500,000. Each unit includes one common share and one transferable warrant exercisable at $0.25 until October 27, 2028. Proceeds are earmarked for inventory, marketing and investor relations, working capital, and general corporate purposes. The company paid finder’s fees of $31,374.75. Units were issued under the listed issuer financing exemption (Part 5A of NI 45-106) in British Columbia, and securities issued to Canadian resident subscribers are not subject to resale restrictions.
Antonio Baldassarre signed on behalf of the board.
Positive
- Gross proceeds of $1,500,000
- Issued 10,000,000 units to strengthen working capital
- Warrants exercisable at $0.25 until Oct 27, 2028
- Canadian subscriber units not subject to resale restrictions
Negative
- Issued 10,000,000 new shares causing immediate dilution
- Potential issuance of 10,000,000 additional shares if warrants exercised
- Paid finder’s fees of $31,374.75 reducing net proceeds
News Market Reaction 1 Alert
On the day this news was published, UDOCF declined 5.12%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
VANCOUVER, BC / ACCESS Newswire / October 27, 2025 / UniDoc Health Corp. (CSE:UDOC)(FRA:L7T)(OTCQB:UDOCF) ("UniDoc" or the "Company") is pleased to announce that it has closed its previously announced non-brokered private placement LIFE offering (the "Offering") by issuing 10,000,000 units (each a "Unit") at a price of
Each Unit consists of one common share in the capital of the Company and one transferrable common share purchase warrant (a "Warrant"). Each Warrant entitles the holder to acquire an additional common share at a price of
The Company plans to use the proceeds from the Offering for inventory, marketing and investor relations services, working capital, and general corporate purposes.
In connection with the Offering, the Company paid
The Units were issued pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106 - Prospectus Exemptions ("NI 45-106") in the province of British Columbia. Pursuant to NI 45-106, the securities forming part of the Units issued to Canadian resident subscribers under the Offering are not subject to resale restrictions.
On Behalf of the Board of Directors,
~Antonio Baldassarre~
Antonio Baldassarre
CEO, President & Director
UniDoc Health Corp.
About UniDoc Health Corp. (CSE:UDOC)(FRA:L7T)(OTCQB:UDOCF)
UniDoc is developing an eHealth solution which is being designed as a self-contained remote virtual clinic within a private kiosk for patients to undergo full consultations as if they were present in a physician's office. eHealth opens the doors to a large segment of the population challenged by access, experience or understanding of online computer technology. It is the Company's belief that physical accessibility is the key to its business proposition. UniDoc is dedicated to unlocking shareholder value by delivering an excellent product and sophisticated commercial network within an expedited timeframe. The UniDoc team encourages engagement, questions, and interest, so please stay in touch and invite anyone who might be interested in our story to visit our website at www.unidoctor.com and signup to receive the latest information with updates on our activities, events and progress.
For further information, please contact:
UniDoc Investor Relations
Tel: +1 778.383.6731
Email: info@unidoctor.com
Matt Chatterton, Director
Tel: +1 778.613.2082
Email: matt@unidoctor.com
Media Inquiries media@unidoctor.com
Certain information contained herein constitutes "forward-looking information" under Canadian securities legislation. Forward-looking information includes, but is not limited to: the use of proceeds of the Offering. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "anticipates", "anticipated" "expected" "intends" "will" or variations of such words and phrases or statements that certain actions, events or results "will" occur. Forward-looking statements are based on the opinions and estimates of management as of the date such statements are made and they are from those expressed or implied by such forward-looking statements or forward-looking information subject to known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different, including receipt of all necessary regulatory approvals. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.
The CSE does not accept responsibility for the adequacy or accuracy of this release.
SOURCE: UniDoc Health Corp.
View the original press release on ACCESS Newswire
FAQ
What did UniDoc (UDOCF) announce on October 27, 2025?
What are the warrant terms in the UniDoc LIFE offering (UDOCF)?
How will UniDoc (UDOCF) use proceeds from the LIFE offering?
How much did UniDoc (UDOCF) pay in finder’s fees for the offering?
Are the securities from UniDoc’s (UDOCF) offering subject to resale restrictions?
